Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × brolucizumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neurofibromatosis 2 1 Macular Degeneration 1

Interventions

Cyclophosphamide 358 Carboplatin 303 pembrolizumab 282 Cisplatin 282 Gemcitabine 280 Radiotherapy 269 Paclitaxel 266 Docetaxel 255 Bevacizumab 226 Rituximab 211 Capecitabine 202 Nivolumab 192 Dexamethasone 183 Fluorouracil 177 fludarabine 163 Oxaliplatin 157 Doxorubicin 140 Irinotecan 135 Leucovorin 133 Etoposide 130 Pemetrexed 128 Cytarabine 124 Bortezomib 116 fludarabine phosphate 114 Lenalidomide 111 Filgrastim 110 Cetuximab 110 Erlotinib Hydrochloride 107 Temozolomide 104 Radiation 101

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03710564 2023-01-30

MERLIN

Novartis

Phase 3 Terminated

535 enrolled 14 charts

Macular Degeneration, Neurofibromatosis 2

Data powered by HemOnc (CC BY 4.0) Colophon ⚡